Tirzepatide, the active ingredient in Zepbound and Mounjaro, produces the most weight loss and the largest blood sugar reductions of any GLP-1 medication currently available. In clinical trials, it delivered 15% to nearly 21% body weight loss over 72 weeks, compared to roughly 15% for semaglutide (Wegovy) at its highest dose. But “best” depends on what you’re treating, what your insurance covers, and how your body responds, so the full picture matters.
How the Major GLP-1 Drugs Compare for Weight Loss
Tirzepatide stands at the top of the weight loss rankings right now. In the SURMOUNT trials, people taking it lost between 15% and nearly 21% of their body weight over 72 weeks, depending on the dose. For someone starting at 250 pounds, that translates to roughly 37 to 52 pounds. Tirzepatide works differently from older GLP-1 drugs because it activates two hormone receptors (GLP-1 and GIP) instead of one, which appears to amplify its effects on appetite and metabolism.
Semaglutide, sold as Wegovy for weight management and Ozempic for diabetes, is the next most effective option. At its highest dose, it typically produces around 15% body weight loss over a similar timeframe. That’s still a substantial result and enough to meaningfully improve obesity-related health conditions. Older GLP-1 drugs like liraglutide (Saxenda) and dulaglutide (Trulicity) produce more modest weight loss, generally in the 5% to 10% range.
Which Works Best for Blood Sugar Control
For people with type 2 diabetes, the gap between these drugs is even clearer. A large network meta-analysis published in The BMJ found that tirzepatide reduced HbA1c (a measure of average blood sugar over three months) by 2.10 percentage points, the largest drop of any GLP-1 drug studied. Semaglutide came in second at 1.40 points, and dulaglutide third at 1.09 points. To put that in perspective, a 2-point HbA1c drop could take someone from poorly controlled diabetes to near their target range.
Heart and Kidney Protection
GLP-1 drugs do more than lower weight and blood sugar. As a class, they reduce the risk of major cardiovascular events like heart attack, stroke, and cardiovascular death by about 14%. They also slow kidney disease progression, cutting the risk of worsening kidney outcomes by 24%. These benefits have been demonstrated across multiple large trials and are a major reason doctors now prescribe GLP-1 drugs even to patients whose blood sugar is reasonably well controlled. Semaglutide has the most cardiovascular outcome data so far, though tirzepatide trials are ongoing.
Oral Tablets vs. Injections
Most GLP-1 drugs are weekly injections, but semaglutide also comes in a daily oral tablet (Rybelsus). Research reviews have found that oral semaglutide is similarly effective to injectable versions for both weight loss and blood sugar reduction. The tradeoff is convenience in a different direction: the tablet must be taken first thing in the morning on an empty stomach, and you can’t eat or drink anything for 30 minutes afterward. Injections, by contrast, can be taken at any time regardless of meals. If needles are a dealbreaker for you, oral semaglutide is a legitimate alternative, though the strict dosing routine can be its own challenge.
How Dosing Works
Both semaglutide and tirzepatide start at low doses and gradually increase over several months. Semaglutide begins at 0.25 mg per week and climbs in 0.25 mg steps every four weeks, reaching a maximum of 2.4 mg over roughly 16 to 20 weeks. Tirzepatide starts at 2.5 mg per week and increases in 2.5 mg steps, maxing out at 15 mg. This slow ramp-up exists to minimize nausea and other gastrointestinal side effects, which are the most common reason people stop treatment early. Most people find the side effects manageable once their body adjusts to each new dose level.
Cost and Insurance Coverage
Price is often the deciding factor. Without insurance, GLP-1 medications can cost over $1,000 per month. Coverage varies widely by plan, and many insurers require prior authorization showing that you meet specific criteria before they’ll pay.
Medicare recently launched a GLP-1 Bridge program that caps the net price at $245 per monthly supply, with a $50 copay for eligible beneficiaries. To qualify, you generally need a BMI of 35 or higher, or a BMI of 30 or higher with certain conditions like uncontrolled high blood pressure, heart failure, or chronic kidney disease. People with a BMI of 27 or higher can qualify if they have pre-diabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease. Private insurance criteria vary but follow similar patterns, typically requiring a documented BMI threshold plus a weight-related health condition.
Safety Considerations
All GLP-1 drugs carry an FDA boxed warning about thyroid tumors. They should not be used by anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. The risk was identified in animal studies, and while it hasn’t been confirmed in humans, the warning remains as a precaution.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be worst during the dose escalation phase and improve over time. More serious but rare complications include pancreatitis and gallbladder problems, which is why doctors monitor for unusual abdominal pain during treatment.
What’s Coming Next
Retatrutide, an investigational drug from Eli Lilly, activates three hormone receptors instead of two. In a phase 3 trial of people with obesity and knee osteoarthritis, the higher dose produced an average weight loss of 28.7%, or about 71 pounds, over 68 weeks. Nearly 40% of participants on the higher dose lost 30% or more of their body weight. If approved, retatrutide would represent a significant jump beyond what tirzepatide achieves today. It’s not yet available, but it signals where this drug class is heading.
Picking the Right One
If maximum weight loss is your primary goal and you have access, tirzepatide (Zepbound) currently delivers the best results. If you’re managing type 2 diabetes, tirzepatide (Mounjaro) again leads the field for blood sugar reduction, though semaglutide (Ozempic) has a longer track record and more cardiovascular outcome data. For people who want to avoid injections, oral semaglutide (Rybelsus) offers comparable efficacy with a different set of daily logistics.
In practice, the “best” GLP-1 drug is often the one your insurance will cover at a price you can sustain, because these medications need to be taken long term to maintain their benefits. Weight tends to return after stopping treatment, which makes affordability and access just as important as raw efficacy numbers when making your choice.